zanzalintinib Updated Jun 30
Watch the PDUFA date (December 3, 2026) closely as the key binary. The STELLAR-303 split results (ITT positive, NLM subgroup negative) complicate FDA approval odds but analysts suggest approval is still possible given the positive ITT data. Monitor for an FDA Advisory Committee date and any additional communications from the FDA. Elevated short interest (~55-60% short ratio) suggests the market is skeptical, creating potential for a squeeze on positive news, but equally large downside if the FDA issues a CRL.
- Zanzalintinib demonstrated a statistically significant 20% reduction in risk of death (HR 0.80; P=0.0045) in the full ITT population of STELLAR-303, making it the first immunotherapy-based regimen to show an OS benefit in MSS/MSI-low metastatic CRC (source: ir.exelixis.com press release Oct 2025).
- The FDA accepted the NDA with a PDUFA date of December 3, 2026, and at least two groups of analysts suggested approval is still on the table despite the split results, noting the positive ITT data provides a strong efficacy signal (source: Fierce Biotech June 2026).
- Exelixis has a massive pipeline expansion path beyond CRC, ongoing STELLAR-311 Phase 3 in neuroendocrine tumors, plus planned Phase 3 trials in squamous NSCLC and mCRPC in H2 2026, offering multiple shots on goal (source: intellectia.ai earnings summary May 2026).
- The final analysis of STELLAR-303 failed its dual primary endpoint, OS in patients without liver metastases was not statistically significant (HR 0.83; 95% CI 0.66-1.05; P=0.1185), which Fierce Biotech characterized as a clinical 'failure' and creates material FDA approval risk (source: biospace.com press release June 22, 2026; Fierce Biotech June 22, 2026).
- Truist Securities downgraded EXEL from Buy to Hold on June 25, 2026 following the disappointing STELLAR-303 final analysis, and the consensus analyst price target of $49.50 sits below the current ~$54 stock price, suggesting limited near-term upside.
- Multiple insiders sold shares in May-June 2026, including R&D head Dana Aftab (43,451 shares at $50.35), CFO Patrick Haley (32,110 shares), and directors George Poste (60,000 shares), a coordinated wave of selling ahead of the negative data readout.